[18f]fdg Alliance Medical

Fludeoxyglucose (18F) is a radiopharmaceutical used in PET scans for metabolic imaging. It helps detect abnormal metabolic activity in tissues, commonly for cancer diagnosis and monitoring. This product is supplied by Alliance Medical Rp Berlin GmbH. Suitable for intravenous administration only.

Fludeoxyglucose (18F) is primarily used in positron emission tomography (PET) scans to identify areas of abnormal metabolic activity. It is commonly employed in oncology for detecting cancer, assessing treatment response, and monitoring recurrence. The radiopharmaceutical is also used in cardiology and neurology for evaluating conditions like coronary artery disease and epilepsy.

After intravenous injection, Fludeoxyglucose (18F) distributes throughout the body, accumulating in tissues with high metabolic rates, such as the brain and certain tumors. The imaging process captures these areas, highlighting potential abnormalities. Patients may experience mild discomfort at the injection site, but the radiopharmaceutical itself does not produce noticeable effects.

Fludeoxyglucose (18F) should only be handled and administered by trained healthcare professionals. Patients should inform their provider of any allergies, especially to medications or contrast agents. Pregnant or breastfeeding individuals should discuss risks with their doctor before use. The product must be stored and transported under controlled conditions to maintain its integrity.

Fludeoxyglucose (18F) does not interact with medications in the traditional sense, as it is a diagnostic agent. However, certain medications or conditions may affect imaging results, such as high blood sugar levels or recent chemotherapy. Patients should follow their provider’s instructions regarding fasting or medication adjustments prior to the scan.